Corpus Luteum Function and Cardiovascular Adaptation in a Natural MOCK Cycle. (CLEAR)
tiistai 9. kesäkuuta 2026 päivittänyt: Noa Wauters, Universitair Ziekenhuis Brussel
In infertility treatment, embryos are created in vitro after eggs have been fertilised by sperm using in vitro fertilisation or intracytoplasmic sperm injection techniques.
These embryos, resulting from hormonal ovarian stimulation, can be transferred shortly after egg retrieval (fresh transfer) or frozen for later use.
Both natural menstrual cycles and artificial cycles (using hormones to mimic a normal cycle) can prepare the uterus for embryo transfer.
Patients with regular menstrual cycles often prefer the non-medicated approach.
However, these cycles offer less flexibility in timing because they rely on ovulation.
As the number of FET cycles increases worldwide, scientists are exploring the possibility of inducing ovulation in smaller follicles to increase the flexibility of natural cycles.
However, the safety for future pregnancies is unknown.
This study aims to better understand the function of the corpus luteum, the follicle remnant in the ovary after ovulation, by measuring several factors that change throughout the cycle due to substances produced by the corpus luteum.
The results of the study will have a direct impact on clinical practice by increasing the flexibility of frozen transfer cycles.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Opintotyyppi
Havainnollistava
Ilmoittautuminen (Arvioitu)
118
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Caroline Roelens
- Puhelinnumero: 0032 2 477 9887
- Sähköposti: caroline.roelens@uzbrussel.be
Opiskelupaikat
-
-
-
Jette, Belgia, 1090
- UZ Brussel
-
Ottaa yhteyttä:
- Caroline Roelens
- Puhelinnumero: 0032 2 477 9887
- Sähköposti: caroline.roelens@uzbrussel.be
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Näytteenottomenetelmä
Todennäköisyysnäyte
Tutkimusväestö
Our study population pertains to female patients and volunteers, of the age between 18 years old and 40 years old, with a regular menstrual cycle (25-35 days) and a normal BMI (18.5-35).
You are eligible if you have not used any form of hormonal contraception or copper IUD throughout the last 3 months, have not had an ovarian stimulation during this time period, and are not known with renal or cardiac disease, diabetes or hypertension.
Kuvaus
Inclusion Criteria:
- Age below 40 years
- Regular menstrual cycles (between 25-35 days)
- Normal BMI between 18.5 and 35
Exclusion Criteria:
- Underlying renal or cardiac disease
- Hypertension
- Diabetes mellitus
- Contraceptive use less than 3 months before MOCK cycle, including: IUD (hormonal and copper), hormonal patch, contraceptive pill (combination and mini), hormonal intravaginal ring, contraceptive implant, contraceptive injection.
- Ovarian stimulation during the previous three months
- History of recurrent pregnancy loss (defined as 2 or more previous pregnancy losses before 24 weeks gestation).
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Follicle size 11mm
Patients with a follicle of 11mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 12 mm
Patients with a follicle of 12mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 13 mm
Patients with a follicle of 13mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 14 mm
Patients with a follicle of 14mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 15 mm
Patients with a follicle of 15mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 16 mm
Patients with a follicle of 16mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 17 mm
Patients with a follicle of 17mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
|
Follicle size 18 mm
Patients with a follicle of 18mm when measured through transvaginal ultrasound in 2D, at time of ovulation induction.
|
We will collect several blood samples:
A transvaginal ultrasound will be performed after day 8 of the cycle to evaluate a 2D measurement of the growing follicle, as well as a measurement of the endometrial thickness to evaluate readiness for ovulation induction.
The MAP will be measured at cycle day 7 and 7 days post-ovulation induction to follow cardiovascular adaptations.
When patient is deemed ready for ovulation based on follicle size, blood results and endometrium, she will be asked to inject Ovitrelle 250 micrograms to induce ovulation in a controlled and timed manner.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
The relationship between progesterone levels and different follicular sizes on day 7 post ovulation induction.
Aikaikkuna: From the start of the menstrual cycle until 7 days after ovulation induction.
|
Progesterone levels will be measured 7 days after ovulation induction to relate them to different follicular sizes.
|
From the start of the menstrual cycle until 7 days after ovulation induction.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Estradiol evolution throughout the cycle and its relation to luteal progesterone levels.
Aikaikkuna: From the start of a menstrual cycle until 7 days post-ovulation induction.
|
We will measure the estradiol on different moments throught the menstural cycle, and see how these levels correspond to later (luteal) progesterone levels.
|
From the start of a menstrual cycle until 7 days post-ovulation induction.
|
|
Indirect factors reflecting cardiovascular and renal adaptation in the luteal phase
Aikaikkuna: From the start of the menstrual cycle until 7 days after ovulation induction.
|
We will measure these factors (MAP, progesterone, estradiol, serum sodium, chloride, carbon dioxide and osmolality, prolactin, direct renin, plasma aldosterone, NT-proBNP, relaxin-2 and VEGF) at day 8 of the cycle, as well as 7 days after ovulation-induction.
All these factors form a reflection of the body's cardiovascular and renal adaptation, and will be studied to estimate these adaptation at different follicular sizes.
|
From the start of the menstrual cycle until 7 days after ovulation induction.
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Keskiviikko 1. heinäkuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Tiistai 1. helmikuuta 2028
Opintojen valmistuminen (Arvioitu)
Perjantai 1. syyskuuta 2028
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 9. kesäkuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 9. kesäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Maanantai 15. kesäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Maanantai 15. kesäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 9. kesäkuuta 2026
Viimeksi vahvistettu
Maanantai 1. kesäkuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Hormonit
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Peptidihormonit
- Peptidit
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Tutkintatekniikat
- Terapeuttiset lääkkeet
- Näytteenkäsittely
- Kliiniset laboratoriotekniikat
- Diagnostiikkatekniikat ja menettelyt
- Diagnoosi
- Puhkaisut
- Kirurgiset toimenpiteet, operatiivinen
- Lisääntymistekniikat, avustetut
- Lisääntymistekniikat
- Gonadotropiinit
- Istukanhormonit
- Raskausproteiinit
- Koriongonadotropiini
- Verinäytteen kokoelma
- Ovulaation induktio
Muut tutkimustunnusnumerot
- EC-2025-445
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .